Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ECOR NASDAQ:IRIX NASDAQ:NDRA NASDAQ:SLNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeECORelectroCore$6.27$6.44$4.16▼$8.64$52.04M0.6859,931 shs182,555 shsIRIXIRIDEX$1.01$1.12$0.87▼$1.65$17.57M0.6455,237 shs20,713 shsNDRAENDRA Life Sciences$5.05$4.57$2.91▼$11.96$6.26M-0.1116,717 shs44,977 shsSLNOSoleno Therapeutics$53.01$44.97$29.43▼$90.32$2.76B-2.221.91 million shs4.96 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceECORelectroCore0.00%-2.18%-3.54%+15.47%+16.11%IRIXIRIDEX0.00%-1.94%-4.72%-26.81%0.00%NDRAENDRA Life Sciences0.00%+2.02%-21.09%+43.87%+56.35%SLNOSoleno Therapeutics0.00%+0.11%+0.44%+42.35%-29.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeECORelectroCore$6.27$6.44$4.16▼$8.64$52.04M0.6859,931 shs182,555 shsIRIXIRIDEX$1.01$1.12$0.87▼$1.65$17.57M0.6455,237 shs20,713 shsNDRAENDRA Life Sciences$5.05$4.57$2.91▼$11.96$6.26M-0.1116,717 shs44,977 shsSLNOSoleno Therapeutics$53.01$44.97$29.43▼$90.32$2.76B-2.221.91 million shs4.96 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceECORelectroCore0.00%-2.18%-3.54%+15.47%+16.11%IRIXIRIDEX0.00%-1.94%-4.72%-26.81%0.00%NDRAENDRA Life Sciences0.00%+2.02%-21.09%+43.87%+56.35%SLNOSoleno Therapeutics0.00%+0.11%+0.44%+42.35%-29.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceECORelectroCore 2.00Hold$18.00187.08% UpsideIRIXIRIDEX 2.00Hold$3.00197.03% UpsideNDRAENDRA Life Sciences 2.00Hold$30.00494.06% UpsideSLNOSoleno Therapeutics 2.08Hold$76.6744.63% UpsideCurrent Analyst Ratings BreakdownLatest NDRA, SLNO, ECOR, and IRIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026SLNOSoleno Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/4/2026IRIXIRIDEX Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026NDRAENDRA Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026SLNOSoleno Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight ➝ Equal Weight$110.00 ➝ $53.004/17/2026SLNOSoleno Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$110.00 ➝ $53.004/8/2026SLNOSoleno Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$100.00 ➝ $53.004/7/2026SLNOSoleno Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/7/2026SLNOSoleno Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$85.00 ➝ $53.004/7/2026SLNOSoleno Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Hold4/6/2026SLNOSoleno Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/6/2026SLNOSoleno Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookECORelectroCore$32.03M1.62N/AN/A($0.21) per share-29.86IRIXIRIDEX$52.67M0.33N/AN/A($0.06) per share-16.83NDRAENDRA Life SciencesN/AN/AN/AN/A$1.92 per shareN/ASLNOSoleno Therapeutics$190.40M14.51$0.43 per share124.10$8.38 per share6.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateECORelectroCore-$13.97M-$1.77N/AN/AN/A-44.08%-1,956.38%-83.30%8/5/2026 (Estimated)IRIXIRIDEX-$4.44M-$0.26N/AN/AN/A-8.42%-1,204.74%-14.39%5/19/2026 (Estimated)NDRAENDRA Life Sciences-$7.03M-$8.92N/AN/AN/AN/A-397.71%-190.73%N/ASLNOSoleno Therapeutics$20.89M$1.7729.959.89N/A33.70%22.85%18.25%8/5/2026 (Estimated)Latest NDRA, SLNO, ECOR, and IRIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2026Q1 2026IRIXIRIDEX-$0.07N/AN/AN/A$11.91 millionN/A5/15/2026Q1 2026NDRAENDRA Life Sciences-$1.23-$1.09+$0.14-$1.09N/AN/A5/6/2026Q1 2026ECORelectroCore-$0.59-$0.59N/A-$0.59$9.01 million$9.58 million3/26/2026Q4 2025IRIXIRIDEX-$0.02-$0.01+$0.01-$0.01$14.74 million$14.72 million3/19/2026Q4 2025ECORelectroCore-$0.35-$0.34+$0.01-$0.34$9.09 million$9.24 million2/25/2026Q4 2025SLNOSoleno Therapeutics$0.64$0.80+$0.16$0.80$88.55 million$91.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthECORelectroCoreN/AN/AN/AN/AN/AIRIXIRIDEXN/AN/AN/AN/AN/ANDRAENDRA Life SciencesN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioECORelectroCoreN/A1.020.86IRIXIRIDEXN/A1.911.32NDRAENDRA Life SciencesN/A1.291.29SLNOSoleno Therapeutics0.105.625.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipECORelectroCore26.74%IRIXIRIDEX20.10%NDRAENDRA Life Sciences1.19%SLNOSoleno Therapeutics97.42%Insider OwnershipCompanyInsider OwnershipECORelectroCore13.80%IRIXIRIDEX8.60%NDRAENDRA Life Sciences10.00%SLNOSoleno Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableECORelectroCore508.30 million7.15 millionNot OptionableIRIXIRIDEX12017.40 million15.90 millionOptionableNDRAENDRA Life Sciences201.24 million1.12 millionNot OptionableSLNOSoleno Therapeutics3052.12 million48.78 millionOptionableNDRA, SLNO, ECOR, and IRIX HeadlinesRecent News About These CompaniesSLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens BermanMay 11, 2026 | prnewswire.comF m Investments LLC Sells 25,859 Shares of Soleno Therapeutics, Inc. $SLNOMay 11, 2026 | marketbeat.comSoleno Merger With Neurocrine Puts Profitability And Valuation In FocusMay 10, 2026 | finance.yahoo.comSoleno Therapeutics Target of Unusually High Options Trading (NASDAQ:SLNO)May 6, 2026 | marketbeat.comSOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNOMay 5, 2026 | newsfilecorp.comNSOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNOMay 5, 2026 | newsfilecorp.comNINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNOMay 5, 2026 | globenewswire.comSLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class ActionMay 5, 2026 | prnewswire.comDEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersMay 5, 2026 | globenewswire.comSLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law FirmMay 5, 2026 | prnewswire.comPortnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. InvestorsMay 5, 2026 | globenewswire.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Rating of "Hold" from AnalystsMay 5, 2026 | marketbeat.comSOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNOMay 4, 2026 | newsfilecorp.comNSOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff DeadlineMay 4, 2026 | globenewswire.comDeadline Soon: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitMay 4, 2026 | tmcnet.comSOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNOMay 4, 2026 | globenewswire.comSLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026May 4, 2026 | newsfilecorp.comNBronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmMay 4, 2026 | globenewswire.comSLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud LawsuitMay 4, 2026 | prnewswire.comSLNO SHAREHOLDER NOTICE: Hagens Berman Alerts Soleno (SLNO) Investors to Pending Securities Fraud Class Action and Upcoming May 5th Lead Plaintiff DeadlineMay 4, 2026 | globenewswire.comSoleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNOMay 4, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesVerizon’s Signal Strength: The Turnaround Call Is Loud and ClearBy Jeffrey Neal Johnson | April 30, 2026Rocket Lab Posts Record Q1 Revenue, Raises Q2 GuidanceBy Ryan Hasson | May 8, 2026Oracle Bottoms: A Multi-Cloud Future Is Ahead—and UndervaluedBy Thomas Hughes | April 20, 2026Verizon Q1 Earnings Dip—A Buying Opportunity for VZ Stock?By Thomas Hughes | April 28, 2026GE Vernova Beats Earnings by 790% as Data Center Demand ExplodesBy Chris Markoch | April 23, 2026NDRA, SLNO, ECOR, and IRIX Company DescriptionselectroCore NASDAQ:ECOR$6.27 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$6.25 -0.02 (-0.32%) As of 05/15/2026 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.IRIDEX NASDAQ:IRIX$1.01 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.01 0.00 (0.00%) As of 06:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.ENDRA Life Sciences NASDAQ:NDRA$5.05 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$5.10 +0.04 (+0.89%) As of 05/15/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.Soleno Therapeutics NASDAQ:SLNO$53.01 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$53.01 +0.00 (+0.01%) As of 05/15/2026 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
